ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.34% Direct Plan: 0.43%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	183.39
AAUM (in Rs. Cr):	173.90
% of top 5 holdings:	40.68%
% of top 10 holdings:	58.72%
No. of scrips:	40

Standard Deviation^:	NA
Beta^:	NA
*Sharpe Ratio^:**	NA
Average P/B	7.65
Average P/E	44.10
Portfolio Turnover Ratio	0.57
^Scheme has not completed 3 years hence NA * Risk free rate: 6.55 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	15.6301	16.5490
IDCW:	15.6301	16.5490

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	98.65
Chemicals	3.07
Archean Chemical Industries Limited	2.02
Sumitomo Chemical India Limited	1.06
Healthcare	95.57
Sun Pharmaceutical Industries Limited	15.97
Dr. Reddy's Laboratories Limited	7.20
Lupin Limited	6.39
Apollo Hospitals Enterprise Limited	5.63
Suven Pharmaceuticals Limited	5.49
Divi's Laboratories Limited	4.49
Zydus Lifesciences Limited	4.18
Max Healthcare Institute Limited	3.31
Cipla Limited	3.15
Laurus Labs Limited	2.91
Syngene International Limited	2.65
Torrent Pharmaceuticals Limited	2.48
Alembic Pharmaceuticals Limited	2.11
Piramal Pharma Limited	1.99
Orchid Pharma Limited	1.98
FDC Limited	1.79
Aurobindo Pharma Limited	1.78
IPCA Laboratories Limited	1.63
Healthcare Global Enterprises Limited	1.53
Biocon Limited	1.39
GlaxoSmithKline Pharmaceuticals Limited	1.37
Ajanta Pharma Limited	1.34
Mankind Pharma Limited	1.33
Vijaya Diagnostic Centre Limited	1.30
Caplin Point Laboratories Limited	1.27
Abbott India Limited	1.13
JB Chemicals & Pharmaceuticals Limited	1.04
Shilpa Medicare Limited	1.01
Fortis Healthcare Limited	0.98
Alkem Laboratories Limited	0.94
Rainbow Childrens Medicare Limited	0.94
Gland Pharma Limited	0.93
Strides Pharma Science Limited	0.86
Wockhardt Limited	0.74
Sanofi India Limited	0.70
Emcure Pharmaceuticals Limited	0.67
Supriya Lifescience Limited	0.56
Sanofi Consumer Healthcare India Limited	0.40
Short Term Debt & Net Current Assets	1.35

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	43.2%	44.4%	27.8%	14,334	14,457	12,784
Since Inception	17.8%	19.4%	13.9%	15,630	16,239	14,263
Direct - Growth
Last 1 Year	45.9%	44.4%	27.8%	14,610	14,457	12,784
Since Inception	20.3%	19.4%	13.9%	16,549	16,239	14,263

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 3 years period has not been provided, since scheme is in existence for less than 3 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. ITI Pharma & Healthcare Fund NAV as on July 31, 2024: Rs. 15.6301 (Regular Growth Option), Rs. 16.5490 (Direct Growth Option)

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	120,000	152,754	54.25%	153,828	56.14%	142,084	35.84%
Since Inception	330,000	501,488	32.15%	512,319	33.94%	447,494	22.88%
Direct - Growth
Last 1 Year	120,000	154,411	57.17%	153,828	56.14%	142,084	35.84%
Since Inception	330,000	516,955	34.70%	512,319	33.94%	447,494	22.88%

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).